Table 3.
Evolution of HPV-related infections in the study period depending on specific HPV genotype. Analytical results of the studied groups. All cases were positive for the specified HPV subtype (16, 18, 31, 33, or 45) before vaccination. N: number of cases within each study group, OR: odds ratio, RR: relative risk, ARR: absolute relative risk, NNT: number needed to treat, CI: confidence interval, V1: vaccinated women with HPV DNA-positive and mRNA-negative results, NV1: non-vaccinated women with HPV DNA-positive and mRNA-negative results, V2: vaccinated women with HPV DNA- and mRNA-positive results, NV2: non-vaccinated women with HPV DNA- and mRNA-positive results.
| HPV Genotype (N, %) | Group | N | HPV DNA+ at 12 Months (N, %) | HPV DNA Clearance (%) | HPV mRNA+ at 12 Months (N, %) | p-value * | OR (95% CI) | RR (95% CI) | ARR (95% CI) | NNT (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 (77, 24.92%) | V1 | 24 | 4, 16.67% | 83.33% | 0, 0% | 0.043 | 4.333 (1.175 to 15.986) | 1.556 (1.055 to 2.294) | −0.298 (−0.501 to −0.042) | −3 (−2 to −24) |
| NV1 | 28 | 13, 46.43% | 53.57% | 3, 10.71% | ||||||
| V2 | 12 | 6, 50% | 50.00% | 4, 33.33% | 0.567 | 2.25 (0.439 to 11.522) | 1.625 (0.602 to 4.384) | −0.192 (−0.498 to 0.172) | −5 (−2 to −6) | |
| NV2 | 13 | 9, 69.23% | 30.77% | 7, 53.85% | ||||||
| 18 (83, 26.86%) | V1 | 25 | 6, 24% | 76.00% | 1, 4% | 0.043 | 4.03 (1.201 to 13.526) | 1.727 (1.054 to 2.831) | −0.12 (−0.534 to −0.049) | −3 (−2 to −21) |
| NV1 | 25 | 14, 56% | 44.00% | 3, 12% | ||||||
| V2 | 13 | 6, 46.15% | 53.85% | 3, 23.08% | 0.672 | 1.75 (1.006 to 21.653) | 1.346 (0.645 to 2.81) | −0.138 (−0.431 to 0.188) | −7 (−2 to −5) | |
| NV2 | 20 | 12, 60% | 40.00% | 7, 35% | ||||||
| 31 (79, 25.57%) | V1 | 28 | 6, 21.43% | 78.57% | 3, 10.71% | 0.036 | 4.481 (1.27 to 15.82) | 1.746 (1.036 to 2.942) | −0.336 (−0.558 to −0.06) | −3 (−2 to −17) |
| NV1 | 20 | 11, 55% | 45.00% | 7, 35% | ||||||
| V2 | 15 | 8, 53.33% | 46.67% | 4, 26.67% | 0.879 | 0.0481 (0.0025 to 0.9314) | 1.244 (0.541 to 2.861) | −0.092 (−0.392 to 0.232) | −11 (−3 to 4) | |
| NV2 | 16 | 10, 62.5% | 37.50% | 8, 50% | ||||||
| 33 (60, 19.42%) | V1 | 18 | 5, 27.78% | 72.22% | 2, 11.11% | 0.407 | 2.311 (0.568 to 9.408) | 1.364 (0.801 to 2.322) | −0.193 (−0.46 to 0.119) | −5 (−2 to 8) |
| NV1 | 17 | 8, 47.06% | 52.94% | 3, 17.65% | ||||||
| V2 | 11 | 5, 45.45% | 54.55% | 5, 45.45% | 0.859 | 1.6 (0.3262 to 7.848) | 1.273 (0.566 to 2.862) | −0.117 (−0.44 to 0.245) | −9 (−2 to 4) | |
| NV2 | 14 | 8, 57.14% | 100.00% | 5, 35.71% | ||||||
| 45 (10, 3.24%) | V1 | 4 | 0, 0% | 100.00% | 1, 25% | 0.343 | 1.2857 (0.02 to 82.497) | 1.029 (0.642 to 1.649) | −0.025 (−0.513 to 0.426) | −40 (−2 to 2) |
| NV1 | 3 | 0, 0% | 100.00% | 1, 33.33% | ||||||
| V2 | 2 | 1, 50% | 50.00% | 1, 50% | 0.665 | 0.333 (0.0066 to 16.80) | 0.5 (0.125 to 0.905) | 0.5 (−0.391 to 0.905) | 2 (−3 to 1) | |
| NV2 | 1 | 0, 0% | 100.00% | 0, 0% |
* P-values indicate results of the chi-squared test of the HPV DNA-positive cases before and after vaccination, statistically significant differences are indicated in bold. A significant reduction in HPV DNA positivity rates was observed in vaccinated individuals only in the V1 Groups (HPV DNA (+) and HPV mRNA (-)] for HPV genotypes 16, 18, and 31.